AbbVie announces over £120 million investment to expand Oxford R&D site
AbbVie said it will invest more than £120 million to open a new 12,000‑square‑foot R&D facility in Oxford, England. The expansion will focus on immunology, neuroscience and oncology and builds on the technology acquired with DJS Antibodies in 2022. The company highlighted its collaboration with more than 100 UK universities and its aim to deepen ties with the UK life‑sciences ecosystem. The move comes as AbbVie reported third‑quarter 2026 revenue of $17.4 billion, up 10% year‑over‑year.
Why it matters
The press release says the investment signals AbbVie’s confidence in the UK biomedical cluster while some peers have paused UK R&D spending, potentially giving AbbVie an early foothold in the region’s talent and research resources.
Key facts
- 1AbbVie will invest more than £120 million. thepharmaletter.com
- 2The investment is approximately $161.7 million. finance.biggo.com
- 3The new Oxford R&D site will be 12,000 square feet. finance.biggo.com
- 4Jon Sedgwick is AbbVie’s global head of drug discovery (senior vice president and global head of discovery research). finance.biggo.com
- 5AbbVie works with more than 100 UK universities and research institutions each year. finance.biggo.com
- 6Third‑quarter 2026 revenue rose 10% year‑over‑year to $17.4 billion. finance.biggo.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.